Ozempic and Mounjaro are both very popular for weight loss at the minute, but there's one big difference between the two ...

Menopause can feel like one big balancing act. Between managing your hormone levels and symptoms like hot flashes, night ...

Postmenopausal women on tirzepatide show lower weight loss than those typically seen with the obesity drug, but weight loss ...

“Weight loss quality is a new concept….The discussion no longer revolves around the lack of adequate efficacy but rather ...

Tirzepatide acts on both GLP-1 and GIP receptors, suggesting enhanced efficacy in appetite regulation. This summary was automatically generated using LLM. Full disclaimer ...

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body weight, food intake and many measures of appetite more than placebo and ...

A 6-week randomized trial found that tirzepatide significantly reduced energy intake, appetite, and cravings in adults with overweight or obesity, outperforming liraglutide and placebo. Brain ...

The drug mimics the GLP-1 hormone in your body which helps regulate insulin and reduces and controls appetite, making you feel full for longer. Tirzepatide is a newer medication that targets two ...

Tirzepatide, sold under the name Zepbound, activates two hormone receptors—GLP-1 and GIP—while semaglutide (Wegovy) only targets GLP-1. Both of these hormones help reduce appetite and regulate ...

New animal research being presented at this year’s European Congress on Obesity (ECO) in Malaga, Spain (11-14 May), reveals distinct metabolic adjustments to tirzepatide and semaglutide ...

Consistent with known effects of GLP-1/GIP therapy, over 50% of lost weight was regained within two weeks of stopping treatment in both the tirzepatide and co-administration arms of the study. In ...

Co-administered bremelanotide + tirzepatide, bremelanotide alone, and tirzepatide alone arms showed improvement in appetite suppression, fullness, and satietyBremelanotide matched or exceeded ...